Inhibitor Therapeutics, Inc.
INTI
$0.0514
-$0.0086-14.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 5.61M | 6.38M | 7.10M | 7.68M | 8.84M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 87.80K | 73.10K | 74.60K | 112.40K | 109.20K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 5.69M | 6.45M | 7.17M | 7.79M | 8.95M |
|
|
|||||
| Total Current Assets | 5.69M | 6.45M | 7.17M | 7.79M | 8.95M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 5.69M | 6.45M | 7.17M | 7.79M | 8.95M |
|
|
|||||
| Total Accounts Payable | 15.90K | 1.70K | 18.80K | 111.90K | 33.70K |
| Total Accrued Expenses | 693.70K | 42.90K | 16.70K | 43.90K | 631.40K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 709.60K | 44.60K | 35.50K | 155.90K | 665.20K |
|
|
|||||
| Total Current Liabilities | 709.60K | 44.60K | 35.50K | 155.90K | 665.20K |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Total Liabilities | 3.71M | 3.04M | 3.04M | 3.16M | 3.67M |
|
|
|||||
| Common Stock & APIC | 54.10M | 54.10M | 54.10M | 54.10M | 54.06M |
| Retained Earnings | -52.12M | -50.70M | -49.97M | -49.46M | -48.78M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 1.99M | 3.41M | 4.14M | 4.64M | 5.28M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.99M | 3.41M | 4.14M | 4.64M | 5.28M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.99M | 3.41M | 4.14M | 4.64M | 5.28M |
|
|
|||||
